MedTrace Logo

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

NCT01966887 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-08-29

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of intracoronary SERCA2a Gene transfer on cardiac volumes and function using multimodality cardiac imaging.

Conditions

  • Heart Failure Congestive
  • Ischemic Cardiomyopathy
  • Non-ischemic Cardiomyopathy

Interventions

GENETIC

MYDICAR-single intracoronary infusion

AAV1/Serca2a

GENETIC

Placebo; single intracoronary infusion

single intracoronary infusion

Sponsors & Collaborators

  • Celladon Corporation

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean-Sébastien HULOT, MDPhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-09-30
Completion
2016-02-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01966887 on ClinicalTrials.gov